Kinase Inhibitor News and Research

RSS

A protein kinase inhibitor is a type of enzyme inhibitor that specifically blocks the action of one or more protein kinases.

Targeting mTOR pathway can improve the effectiveness of chemotherapies for pediatric brain cancer

Two experimental drug approaches that target vulnerabilities in cancer cell metabolism may extend survival and enhance the effectiveness of standard chemotherapies for a highly aggressive type of pediatric brain cancer.

21 May 2021

Screening drug candidates for COVID-19 treatment using computational methods

Researchers identified two potential drug candidates that can inhibit SARS-CoV-2 in vitro. Their combination can work synergistically and increase their inhibitory effect.

19 Apr 2021

Ponatinib identified as a potent inhibitor of SARS-CoV2-induced cytokine storm

Researchers at the Human Biology Division, Fred Hutchinson Cancer Research Center in Washington, United States, found that the FDA-approved, multi-kinase inhibitor Ponatinib is a potent inhibitor of the N-terminal domain (NTD) -mediated cytokine storm. Ponatinib is an oral drug used for the treatment of chronic myeloid leukemia (CML).

14 Apr 2021

Researchers identify several novel SARS-CoV-2 inhibitors

Researchers in London, UK, have identified several compounds with SARS-CoV-2 inhibiting properties, that potentially may be developed into antiviral solutions in the future.

9 Apr 2021

Scientists identify nine potential new COVID-19 treatments

A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has identified nine potential new COVID-19 treatments, including three that are already approved by the Food and Drug Administration (FDA) for treating other diseases.

2 Apr 2021

Targeted drug combined with immunotherapy prolongs survival in patients with advanced kidney cancer

Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.

13 Feb 2021

Researchers develop an easier way to deliver pancreatic cancer drugs

Researchers with the Kansas City Veterans Affairs Medical Center and North Dakota State University have designed a new way to deliver pancreatic cancer drugs that could make fighting the disease much easier.

29 Jan 2021

Drug intervention may prevent heart damage caused by chemotherapy

There could be an intervention on the horizon to help prevent heart damage caused by the common chemotherapy drug doxorubicin, new research suggests.

26 Jan 2021

Combination therapy shows potential for treating lung cancer

Most lung cancers are of a type called non-small-cell lung carcinoma (NSCLC). This type of cancer is relatively insensitive to chemotherapy, so NSCLC therapies are usually based on drug treatment.

22 Jan 2021

New drug reduces tumor volume and pain in patients with neurofibromatosis type 1

Based on preclinical studies of an investigational drug to treat peripheral nerve tumors, researchers at Children's Hospital of Philadelphia (CHOP) as part of the Neurofibromatosis Clinical Trials Consortium have shown that the drug, cabozantinib, reduces tumor volume and pain in patients with the genetic disorder neurofibromatosis type 1 (NF1).

15 Jan 2021

Biologist receives NIH grant to build software tools to predict cancer drug efficacy

One of the most promising areas of human cancer research is the study of signal transduction, or cell signaling.

4 Jan 2021

Study shows low incidence of COVID-19 infection in people with rheumatic diseases

A new study shows that the COVID-19 infection incidence has been low in people with rheumatic diseases, and most of those infected experience a mild course of illness.

6 Nov 2020

New tool can provide non-invasive decision support for NSCLC treatment

Personalized treatment options for patients with lung cancer have come a long way in the past two decades.

16 Oct 2020

Potential drug treatment for AXL-low expressing EGFR-mutated lung cancer

Researchers at Kanazawa University report in Nature Communications the mechanism making some lung-cancer patients resistant to the drug osimertinib.

5 Oct 2020

Automated computational protocol identifies potential SARS-CoV-2 MPro inhibitor

As scientists race to discover new and effective antiviral drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many novel approaches are being utilized. Now, a new study published on the preprint bioRxiv in September 2020 reports on the discovery of a potentially beneficial enzyme blocker that could inhibit SARS-CoV-2 viral replication.

24 Sep 2020

Trial shows new first-line treatment option for patients with metastatic kidney cancer

The results of the phase 3 CheckMate 9ER trial have provided a new first-line treatment option for patients with metastatic kidney cancer. The late breaking results are presented at ESMO 2020.

19 Sep 2020

Animal data supports efficacy of baricitinib vs SARS-COV-2

The high burden of disease caused by the COVID-19 pandemic has led to much research on effective ways to mitigate the health, social, and economic impact of the spread of the infection. A recent study published on the preprint server bioRxiv* in September 2020 reports on the characteristics of the drug baricitinib when used as monotherapy to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Sep 2020

Study: Pleotropic drugs can have both favorable and unfavorable effects on cell growth, survival

The cover for issue 37 of Oncotarget features Figure 7, "The combination of romidepsin and KU60019 is synergistic in a xenograft model of MCL," by Scotto, et al. which reported that the antiproliferative effect induced by histone deactylase inhibitors is associated with the up-regulated expression of the cyclin-dependent kinase inhibitor p21.

17 Sep 2020

SARS-CoV-2 N protein forms biomolecular condensates with viral RNA

Now, a study by researchers from the University of California has shown that the N protein forms biomolecular condensates with the viral RNA in both in vitro and in vivo studies. The research titled, ‘SARS CoV-2 nucleocapsid protein forms condensates with viral genomic RNA’, was published on the preprint server bioRxiv on September 14th, 2020.

15 Sep 2020

Existing drug masitinib identified as potential inhibitor of SARS-CoV-2

Researchers in the United States have demonstrated that a drug originally developed as a treatment for cancer exhibits antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

2 Sep 2020